An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours

Trial Profile

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Volasertib (Primary) ; Itraconazole
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Jun 2018 Planned End Date changed from 15 Jun 2018 to 15 Oct 2018.
    • 08 Mar 2018 Planned End Date changed from 15 Mar 2018 to 15 Jun 2018.
    • 19 Dec 2017 Planned End Date changed from 30 Sep 2017 to 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top